Efficient purification method of recombinant human platelet-derived growth factor BB
Through a simplified three-step process, high-efficiency cation exchange chromatography and gel chromatography, the problem of complex and low efficiency of rhPDGF-BB purification process in the prior art was solved, and an efficient and simplified purification process was achieved, which was suitable for large-scale Production.
Patent Information
- Application Number
- CN202310482065.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-29
- Publication Date
- 2024-11-08
AI Technical Summary
The existing rhPDGF-BB purification process has complicated steps, poor operability and many process parameters, resulting in low purification efficiency, high cost and poor controllability, making it difficult to adapt to the needs of large-scale production.
Using a simplified three-step process: fermentation broth pretreatment (centrifugation and filtration), cation exchange chromatography using high-efficiency porous resin filler POROS XS, and elution by arginine, directly connected to gel chromatography to avoid additional concentration and liquid replacement steps.
An efficient and simplified purification process is achieved, which significantly improves purification efficiency and product purity, reduces process complexity and cost, and is suitable for large-scale production.
Smart Images

Figure CN118909074A_ABST
Abstract
Description
Technical Field
[0001] The invention discloses a protein purification method and belongs to the technical field of protein engineering. Background Art
[0002] Platelet Derived Growth Factor (PDGF) is a dimer formed by two related polypeptide chains connected by disulfide bonds. PDGF is a basic protein stored in platelet a granules. It is released and activated by the disintegrated platelets when the blood coagulates. It has the biological activity of stimulating the chemotaxis of specific cells and promoting the growth of specific cells. PDGF-BB is the most active subtype in the PDGF family and can bind to its tyrosine kinase receptor (RPTKs) to exert biological functions. The PDGF-B gene is located on chromosome 22 and contains 7 exon genes, encoding a precursor protein composed of 241 amino acids. The final mature product formed by protease hydrolysis is a polypeptide composed of 109 amino acids with a molecular weight of 12.3kD. PDGF-BB is a homodimer formed by two PDGF-B monomers through disulfide bonds. Each PDGF-B protein monomer contains 8 highly conserved cysteine residues, of which 6 cysteines form intrachain disulfide bonds in pairs, and the other 2 cross with the corresponding monomers to form interchain disulfide bonds. These intrachain and interchain disulfide bonds constitute the complex spatial structure of the PDGF-BB dimer protein. PDGF-BB can treat the debridement, healing and repair of diabetic acral ulcers in the late stage. It also has great application prospects in the repair and regeneration of severe burns, skin diseases, bone and joint injuries, periodontal disease, etc.
[0003] At present, the production method of rhPDGF-BB is to transfect the target gene from the vector into the engineering host for fermentation expression. Common engineering hosts include Chinese hamster ovary cells (CHO), Saccharomyces cerevisiae, Pichia pastoris and Escherichia coli. Although CHO cells can secrete and express mature glycosylated rhPDGF-BB, they have the disadvantages of high fermentation conditions and costs and low yield. Although Saccharomyces cerevisiae has low fermentation costs and can secrete and express partially glycosylated rhPDGF-BB, its yield is low. The rh PDGF-BB fermented by Escherichia coli is an immature product expressed in the form of inclusion bodies in the cell. In the downstream purification process, it is necessary to add steps such as bacterial cell crushing, inclusion body washing, denaturation, and renaturation. There are disadvantages such as complex and cumbersome purification process and high cost. Pichia pastoris can secrete and express glycosylated rhPDGF-BB with high yield, making it the most commonly used engineering host bacteria. During high-density fermentation, the fermentation broth of rhPDGF-BB contains a large amount of host proteins, nucleic acids, pigments, endotoxins and other impurities, which brings more difficulties to downstream purification. In order to ensure that the purified rhPDGF-BB meets the quality standards specified in the pharmacopoeia, the current common purification process usually contains three chromatography steps, which are divided into crude purification, intermediate purification and fine purification, and are generally formed by a combination of various chromatographic techniques such as ion exchange, hydrophobic and gel chromatography.
[0004] From the existing rhPDGF-BB purification processes, it is necessary to reduce the sample conductivity or adjust the pH before ion exchange chromatography, add high salt before hydrophobic chromatography, and concentrate before gel chromatography. In order to meet the loading conditions of these chromatography steps, additional connection steps such as liquid replacement, dilution, salt supplementation and concentration are added to these processes, resulting in complicated process steps, long purification cycle and poor operability. Another problem caused by the complicated process steps is that there are many process parameters involved, which is not conducive to the full study of key process parameters, poor process controllability and stability, and not conducive to batch consistency after scale-up. For example, CN201310309907.1 discloses a purification process for rh PDGF-BB expressed by Pichia pastoris fermentation. In the fermentation broth pretreatment stage, the centrifugal supernatant needs to undergo complex concentration and filtration steps to meet the low-salt loading conditions of ion exchange chromatography, and then needs to be centrifuged again for clarification, without considering the problem of limited clarification capacity of the centrifuge after scale-up; anion exchange chromatography is followed by cation exchange chromatography, the chromatography principles are similar, the purification efficiency is low, and the cation exchange chromatography requires two steps to wash away impurities, which is cumbersome to operate; in the gel chromatography stage, segmented collection is required, which is not conducive to process amplification, and also results in high residual impurities in the stock solution, such as bacterial endotoxin residues, host protein residues, and host DNA residues, resulting in low specific activity of the stock solution. In addition, CN201410206900.1 discloses a purification process of rhPDGF-BB expressed by Pichia yeast fermentation secretion, which requires adding high salt to the sample before hydrophobic chromatography, and diluting the sample to reduce the salt concentration before cation exchange chromatography; and hydrophobic chromatography uses ethylene glycol, which affects the life of the filler, and is a flammable and explosive reagent, which is not conducive to scale-up. The purification process of rh PDGF-BB disclosed in CN200410068993.2 requires the sample to be replaced with a low-salt solution before cation exchange chromatography, and high salt needs to be added to the sample before hydrophobic chromatography. It also has the technical problems of complex process and incoherent steps. In the purification process of rh PDGF-BB in CN201810886146.9, since the two chromatography steps of anion exchange flow-through and cation exchange adsorption have basically the same principles, the purification efficiency is low, and the sample needs to be diluted before cation exchange chromatography to reduce the salt concentration, and the process steps are incoherent. CN201510135202.1 has a relatively complicated purification process for rh PDGF-BB, and requires the use of protease to remove the fusion tag. The use of protease involves increased costs and the introduction of impurities; in addition, an additional chromatography step is added before and after the removal of the fusion tag. US5759815A requires steps such as washing, denaturation and renaturation of inclusion bodies in the purification process of rh PDGF-BB. The process is relatively complicated, increases the difficulty of operation, and is not conducive to scale-up.
[0005] Based on the above technical problems existing in the prior art, the purpose of the present invention is to provide a step connection process, which is simple to operate, fast and efficient, easy to process control, and suitable for large-scale production of rh PDGF-BB purification process to adapt to the drug production concept of quality by design. Summary of the invention
[0006] Based on the above invention objectives, the present invention first provides a method for purifying platelet-derived growth factor-BB, the method comprising the following steps: (1) Pretreatment of the fermentation broth, including centrifugation of the supernatant and filtration, and obtaining a clarified liquid; in step (1), the clarifying filtration method of the present invention is preferably deep filtration. In addition to deep filtration, it can also include ordinary double-layer membrane filtration and tangential flow filtration (hollow fiber or microfiltration membrane package).
[0007] (2) The clarified liquid obtained in step (1) is subjected to cation exchange chromatography, wherein the filler of the cation exchange chromatography is a strong cation exchange filler with a highly porous rigid resin as a matrix, and the filler has an additional polyhydroxy surface coating to ensure low nonspecific binding. A high density of sulfonic acid functional groups are connected to the filler skeleton, and the ionization of the sulfonic acid functional groups enables the filler to have a cation exchange effect. In a specific embodiment of the present invention, the filler of the cation exchange chromatography is POROS XS (Thermo Company) with a matrix of cross-linked poly (styrene-divinylbenzene). Some other fillers in the art can also be used in the present invention, such as POROS 50HS and POROS 20HS (Thermo Company) whose filler matrix is rigid cross-linked poly(styrene-divinylbenzene); Fractogel EMD SO3 (M / S) (Merck Company) whose filler matrix is rigid cross-linked polymethacrylate resin; Eshmuno CPX / S / CPS (Merck Company) whose filler matrix is rigid polyvinyl ether matrix; Toyopearl SP-650 (M / S) (TOSOH Company) whose filler matrix is rigid polymethacrylate matrix; NanoGel 50SP (Suzhou Nanotech Co., Ltd.) whose filler matrix is rigid monodisperse polystyrene / divinylbenzene (PS-DVB).
[0008] In this step, the concentration of arginine for washing impurities in the cation exchange chromatography process is preferably 0.35 mol / L, and may also include a wider range from 0.2 to 0.5 mol / L. The concentration of arginine for eluting the target protein is preferably 0.8 mol / L, and may also include a wider range from 0.6 to 1 mol / L.
[0009] (3) The eluate obtained in step (2) is subjected to gel chromatography to obtain a platelet-derived growth factor-BB stock solution, wherein the gel chromatography filler is a high-resolution gel filtration filler. In specific applications, gel chromatography fillers of various matrix materials can be selected. In a preferred embodiment of the present invention, a gel filtration filler containing a composite matrix of dextran and agarose can be selected. In a specific embodiment of the present invention, the gel chromatography filler is Superdex 75 prep grade (Cytiva). Superdex 75 prep grade is a preparative-grade gel filtration filler containing a composite matrix of dextran and agarose; the matrix combines the excellent gel filtration chromatography properties of cross-linked dextran (Sephadex) and the physical and chemical stability of highly cross-linked agarose.
[0010] In a preferred technical solution, the composition of the elution buffer in step (2) is (20 mmol / L PB + 0.8 mol / L arginine, pH 7.2).
[0011] More preferably, the elution flow rate of the cation exchange chromatography in step (2) is set to a linear flow rate of 100 cm / h.
[0012] Particularly preferably, in step (2), the chromatography column is first connected to the chromatography system, and the linear flow rate is set to 300 cm / h; the chromatography column is equilibrated with an equilibrium buffer (20 mmol / L PB + 50 mmol / L arginine, pH 7.2) for 3 to 10 CV until the UV280 and the conductivity baseline are stable, and the UV baseline is reset to zero; the clarified liquid is loaded onto the chromatography column; after loading, the column is equilibrated with an equilibrium buffer (20 mmol / L PB + 50 mmol / L arginine, pH 7.2) for 10 to 15 CV; the column is rinsed with a rinse buffer (20 mmol / L PB + 0.35 mol / L arginine, pH 7.2) for 15 CV; and the elution buffer is used for elution for 2 to 3 CV. The target peak is collected, and the collection start and end UV280 is 70 to 50 mAU.
[0013] The buffer system in the purification process of the present invention is preferably a PB system (disodium hydrogen phosphate-sodium dihydrogen phosphate). In addition to the PB buffer system, it may also include a disodium hydrogen phosphate-citric acid buffer system, a citric acid-sodium hydroxide buffer system, a citric acid-sodium citrate buffer system, a disodium hydrogen phosphate-potassium dihydrogen phosphate buffer system, a potassium dihydrogen phosphate-sodium hydroxide buffer system, a sodium barbital-hydrochloric acid buffer system, a Tris-hydrochloric acid buffer system, a glycine-sodium hydroxide buffer system, and a sodium carbonate-sodium bicarbonate buffer system.
[0014] In another preferred technical solution, in step (3), the linear flow rate of gel chromatography is set to "30cm / h"; during chromatography, the chromatography column is first cleaned with 0.5M NaOH for 1~2 CV, and then soaked for at least 30 minutes. Then, the chromatography column is equilibrated with equilibrium buffer (20mmol / LPB + 0.15mol / L NaCl, pH7.2) for 2~3CV until UV280 and the conductivity baseline are stable, and the UV baseline is reset to zero. The IEC eluate is evenly divided into 2 parts, and the gel chromatography column is loaded twice, with the loading volume of each time not exceeding 7%CV. After loading, it is eluted with equilibrium buffer (20mmol / L PB + 0.15mol / L NaCl, pH7.2). The interval between two loadings was at least 1CV; when UV280 began to rise slowly, the rising section of about 20~180mAU was the front impurity peak and was not collected; when UV280 continued to rise, the main elution peak began to be collected, and the section from the peak tip to the descending section, that is, the section of about 180~30mAU, was the elution peak of the target protein. The eluate was collected and sterilized and filtered at 0.22μm to obtain the platelet-derived growth factor-BB stock solution.
[0015] In another preferred technical solution, after step (3), the method further includes a step of flow-through anion composite mode chromatography or anion exchange membrane chromatography.
[0016] More preferably, the anion multimodal chromatography in the flow-through mode uses a multimodal filler composed of a rigid high-flow agarose frame and a novel multimodal ligand N-Benzyl-N-methylethanolamine, for example, Captoadhere or Capto adhere ImpRes chromatography columns (Cytiva), which combine a variety of complex modes of action such as anion exchange, hydrogen bonding and hydrophobicity. In a specific embodiment of the present invention, a Capto adhere chromatography column is used.
[0017] Particularly preferably, the flow rate of the anion composite mode chromatography in the flow-through mode is set to a linear flow rate of 300 cm / h. During the chromatography, the chromatography column is first cleaned with 0.5 M NaOH for 5 CV and then soaked for at least 30 min; the chromatography column is then regenerated with 1 M NaCl for 5 CV; finally, the chromatography column is equilibrated with an equilibrium buffer (20 mmol / L PB + 0.15 mol / L NaCl, pH 7.2) for 10 CV until the UV280 and the conductivity baseline are stable, and the UV baseline is reset to zero; the eluate collected in step (3) is loaded onto the chromatography column, and after loading begins, the flow-through is collected, and when the flow-through UV280 starts to rise, the flow-through liquid is collected in the 50-50 mAU segment; finally, the flow-through liquid is subjected to 0.22 μm sterilization filtration to obtain the platelet-derived growth factor-BB stock solution.
[0018] In a more preferred technical solution, the anion exchange membrane chromatography in the flow-through mode uses a membrane chromatographic filter composed of a membrane with a layer of irreversibly cross-linked strong anion exchanger quaternary ammonium group Q on the surface. In a specific embodiment of the present invention, a Mustang Q membrane chromatographic filter (PALL) is used, and the filter is made of 16 layers of polyethersulfone (PES) material, and the membrane pores are 0.8µm nominal pore size. In an optional technical solution, Sartobind Q or Natrix Q membrane chromatography can also be used. Sartobind Q (Sartorius) is a high-load and high-flow rate membrane chromatographic filter made of regenerated cellulose material, with an inner pore size greater than 3 μm and a quaternary ammonium group Q covalently bound to the membrane surface. The Natrix Q (Merck) is a membrane chromatographic filter made of polypropylene (PP) material, with a membrane pore size of 0.4µm and a quaternary ammonium group Q covalently bound to the membrane surface.
[0019] More preferably, the anion composite mode chromatography of the flow-through mode adopts Mustang Q membrane chromatography with QXT5 specification, in which the membrane volume is 5 ml; the membrane chromatography is connected to the chromatography system, and the membrane volume flow rate is set to 2MV / min; the chromatography column is first cleaned with 0.5M NaOH for 5MV, and then soaked for at least 30min; then the chromatography column is regenerated with 1M NaCl for 5MV; finally, the chromatography column is balanced with equilibrium buffer (20mmol / L PB + 0.15mol / L NaCl, pH7.2) for 10MV, until UV280 and conductivity baseline are stable, and UV baseline is reset to zero. The eluate collected in step (3) is loaded on the membrane chromatography; after loading begins, the flow-through is collected, and when the flow-through UV280 begins to rise, the flow-through liquid is collected in the 50~50mAU section; finally, the flow-through liquid is sterilized and filtered at 0.22μm to obtain platelet-derived growth factor-BB stock solution.
[0020] The present invention provides a PDGF-BB purification process with a simple process and continuous operation, and the process flow has only three steps: clarification and filtration of fermentation supernatant, cation exchange chromatography, and gel chromatography. The present invention specifically optimizes the cation exchange chromatography step for PDGF-BB, and screens and optimizes the cation exchange chromatography filler, elution solvent, and elution flow rate respectively. The optimized cation exchange chromatography step can play a role in connecting the previous and the next steps in the process and running through the entire process.
[0021] First, the cation exchange chromatography is directly connected with the previous fermentation broth clarification step, without the need to change the liquid to adjust the conductivity and pH. The cation exchange chromatography can also be directly connected with the next gel chromatography step without concentration.
[0022] Secondly, the capture chromatography stage has a high loading capacity. The cation exchange chromatography selected in the present invention also has a high dynamic binding loading capacity for PDGF-BB, which can significantly save the cost of using fillers, has a smaller elution volume, and has a high enrichment and concentration effect.
[0023] Third, the capture chromatography stage has a good purification effect The present invention provides a cation exchange chromatography capture method with stronger binding specificity for PDGF-BB. This method has stronger binding force to PDGF-BB, higher target peak elution salt concentration, can effectively avoid most host protein elution ranges, can achieve high separation of PDGF-BB and host protein, can achieve high-purity target protein through only one-step capture chromatography, significantly improves purification efficiency, has simple process, saves cost, and is more operable.
[0024] Fourth, it has stronger elution ability The present invention provides a cation exchange chromatography elution solvent for PDGF-BB, wherein the elution component is alkaline arginine. The elution solvent has a stronger elution ability than sodium chloride and is more suitable for eluting target proteins with strong binding force. In addition, arginine has the function of a protein protectant and can prevent the aggregation and precipitation of PDGF-BB caused by high salt.
[0025] Fifth, no concentration is required before loading on gel chromatography The present invention provides a method for reducing the elution flow rate to reduce the elution volume for cation exchange chromatography of PDGF-BB, so as to further concentrate the eluted sample, and is beneficial to control the gel chromatography loading volume, so as to realize direct loading of the gel chromatography without additional concentration steps. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 . Flow chart of the purification method of platelet-derived growth factor-BB; Figure 2 .Cation exchange chromatography; Figure 3 .Gel chromatography; Figure 4 .SDS-PAGE detection chart of platelet-derived growth factor-BB purified stock solution; Figure 5 .SEC-HPLC purity test result diagram; Figure 6 . Capillary isoelectric focusing iCIEF test results; Figure 7 .POROS XS and Capto SP ImpRes chromatographic comparison chart; Figure 8 .Chromatographic comparison chart of NaCl and arginine as control elution solvents; Fig. 9 .Comparison chart of cation exchange chromatography at different elution flow rates; Fig.10 .Comparison of SDS-PAGE electrophoresis purity of two purification schemes; Fig.11 . SEC-HPLC purity comparison chart of two purification schemes; Fig.12 .Comparison of capillary isotropic focusing purity of two purification schemes. Implementation
[0027] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, these embodiments are merely exemplary and do not constitute any limitation on the scope of protection defined by the claims of the present invention.
[0028] Example 1. Purification method of platelet-derived growth factor-BB The flow chart of the method for purifying platelet-derived growth factor-BB provided by the present invention is as follows Figure 1 The specific steps are as follows: 1. Fermentation broth pretreatment The Pichia pastoris GS115 containing the rh PDGF-BB expression gene (fermentation method and expression sequence see CN200410068993.2) was fermented in a 5L fermenter, and about 3L of fermentation liquid was harvested. The fermentation liquid was centrifuged to obtain 2.6L of centrifugal supernatant, which was clarified and filtered. The clarification and filtration was carried out by connecting a deep filter in series with a sterilizing filter. The membrane area of the deep filter was 115cm 2 , CSD material, H0HP double layer, membrane pore size 0.02~0.2μm filter. Sterile filter using membrane area 20cm 2 , PES material, SLE double layer, membrane pore size 0.45+0.2μm sterilizing filter. Use pipelines to connect the depth filter in the following order: inlet → pump → pressure detector → depth filter → pressure detector → sterilizing filter → outlet. After exhausting with ultrapure water, rinse the depth filter and sterilizing filter thoroughly with 1200ml of ultrapure water. Set the flow rate to 29ml / min (i.e., the depth filter flux is 150LMH). Filter 2.6L of centrifugal supernatant from the inlet, collect the clarified liquid at the outlet, monitor the pressure detector before the depth filter and the sterilizing filter during the filtration process, and the upper limit of the pressure does not exceed 30psi. After all the feed liquid is filtered, use 500~1000ml of ultrapure water for top washing, and then continue to pump in air to push out all the residual feed liquid in the pipeline and filter, and end the filtration. The filtered sample is named "clarified liquid".
[0029] 2. Cation Exchange Chromatography POROS XS chromatography column (Thermo) uses XK16 / 20 column (Cytiva), with a column height of 13 cm and a column volume (CV) of 26 ml. Connect the chromatography column to the chromatography system and set the flow rate to 10 ml / min (linear flow rate 300 cm / h). Use equilibrium buffer (20 mmol / L PB + 50 mmol / L arginine, pH 7.2) to equilibrate the chromatography column for 3-10 CV until UV280 and conductivity baseline are stable, and perform UV baseline zeroing. Load the clarified liquid onto the chromatography column. After loading, use equilibrium buffer (20 mmol / L PB + 50 mmol / L arginine, pH 7.2) to equilibrate for 10-15 CV. Use wash buffer (20 mmol / L PB + 0.35 mol / L arginine, pH 7.2) to wash for 15 CV. Set the elution flow rate to 3.33 ml / min (linear flow rate 100 cm / h), and use elution buffer (20 mmol / L PB + 0.8 mol / L arginine, pH 7.2) for 2-3 CV. Collect the target peak, and the collection start and end UV280 is 70-50 mAU. The collected sample is named "IEC eluate". Figure 2 shows the cation exchange chromatogram, Figure 2 In the figure, the black curve is UV280, the gray curve is conductivity, the abscissa is volume, the UV280 peak of 0~3200ml is the flow-through peak, the UV280 peak of 3500ml is the flushing peak, and the UV280 peak of 3900ml is the flushing peak.
[0030] The preferred cation exchange filler POROS XS of the present invention has a stronger binding force to PDGF-BB, can tolerate the interference of salt concentration in the fermentation broth, has a higher salt concentration for elution of the target peak, can effectively avoid the elution range of most host proteins, can achieve a high degree of separation of PDGF-BB and host proteins, and can achieve high-purity target protein through only one-step capture chromatography, thereby significantly improving the purification efficiency.
[0031] These characteristics are due to the properties of the filler. POROS XS resin is functionalized with a high density of sulfopropyl groups, which are ionized over a wide pH range of 1-14. This gives the resin a high binding capacity over a range of pH and conductivity conditions, increasing the flexibility of method development. The resin backbone of POROS XS consists of a rigid, highly porous, cross-linked poly(styrene-divinylbenzene) with an additional polyhydroxy surface coating to ensure low nonspecific binding. The intrinsic stability and open pore structure of POROS beads allow for rapid binding of macromolecules, consistently producing high dynamic binding capacity under a wide range of flow conditions. Among them, the high density of ligands and the slightly hydrophobic polymer backbone - cross-linked poly(styrene-divinylbenzene) may be the key to the specific adsorption of POROS filler to PDGF-BB (strong hydrophobic protein), which is also the strategy for selecting cation exchange fillers in the present invention.
[0032] 3. Gel chromatography For gel chromatography, Superdex 75 prep grad chromatography column-XK26 / 70 column was selected, with a column height of 60cm and a CV of 320ml. The chromatography column was connected to the chromatography system and the flow rate was set to 2.65ml / min (linear flow rate 30cm / h). The chromatography column was first cleaned with 0.5M NaOH for 1~2 CV, and then soaked for at least 30min. Then the chromatography column was equilibrated with equilibrium buffer (20mmol / L PB + 0.15mol / LNaCl, pH7.2) for 2~3CV until the UV280 and conductivity baselines were stable, and UV baseline was zeroed. The IEC eluate was divided into 2 parts and loaded onto the gel chromatography column twice, with each loading volume not exceeding 7%CV. After loading, it was eluted with equilibrium buffer (20mmol / L PB + 0.15mol / L NaCl, pH7.2). The interval between the two loadings was at least 1CV. When UV280 starts to rise slowly, the rising section of about 20~180mAU is all the front impurity peaks, which are not collected. When UV280 continues to rise, the main elution peak begins to be collected, and the section from the peak tip to the descending section, that is, the section of about 180~30mAU, is the elution peak of the target protein. The collected sample is named "SEC eluate". Finally, the SEC eluate is sterilized and filtered at 0.22μm to obtain the rh PDGF-BB stock solution. Figure 3 Gel chromatography is shown. Figure 3 In the figure, the black curve is UV280, the gray curve is conductivity, the horizontal axis is volume, 0~320ml is the first elution graph, 320~650ml is the second elution graph, Frac is marked as the start of target peak collection, and Waste is marked as the end of target peak collection.
[0033] Example 2. Evaluation of the Purification Effect of rh PDGF-BB Expression Product 1. Recombinant protein SDS-PAGE detection Take 5μg of samples from each process of the purification process and 10μg of the purified stock solution, add them to the electrophoresis precast gel containing SDS (SurePAG, Bis-Tris, 15%, 12 wells), where the loading buffer is 4X LDS Sample Buffer, and put the electrophoresis gel after loading into Tris-MOPS-SDS Running Buffer for SDS-PAGE electrophoresis (180V, 50min). The gel after electrophoresis was stained and destained with eStain L1 protein stainer, and finally the electrophoresis purity was analyzed with gel imager.
[0034] The electrophoresis results are as follows Figure 4 As shown, Figure 4 In the figure, lane 1: clarified solution, lane 2: IEC flow-through solution, lane 3: IEC flushing solution, lane 4: IEC eluate, lane 5: SEC pre-peak impurities, lane 6: empty lane, lane 7: SEC eluate 1, lane 8: empty lane, lane 9: SEC eluate 2, lane 10: empty lane, lane 11: stock solution, lane 12: molecular weight marker. Lane 7 is SEC eluate 1 collected from the first gel chromatography, lane 9 is SEC eluate 2 collected from the second gel chromatography, and lane 11 is the stock solution obtained by combining SEC eluates 1 and 2 and sterilizing and filtering. Almost no impurities other than the main band can be seen.
[0035] 2. Protein concentration detection Use Lowry kit or Bradford kit for detection, load samples into 96-well plate, make protein standard curve, read light absorption value with microplate reader, and calculate protein concentration.
[0036] 3. Bacterial endotoxin detection Bacterial endotoxin detection was performed using the Limulus amebocyte lysate gel method kit produced by Zhanjiang Andus Biological Co., Ltd.
[0037] 4. Host protein residue detection The Pichia pastoris HCPs test is a two-site enzyme-linked immunosorbent assay (ELISA) using a Pichia pastoris host protein residual ELISA kit. The Pichia pastoris HCPs protein contained in the sample reacts simultaneously with horseradish peroxidase labeled with anti-Pichia pastoris antibodies in a microtiter plate that has been previously coated with a layer of adsorbed anti-Pichia pastoris protein antibodies. The immunoreaction is a sandwich structure: solid phase anti-HCP-enzyme labeled antibody. After the reaction, the microtiter plate is washed to remove unbound reactants. TMB is added as a substrate for the reaction. The hydrolysate concentration is measured on a microtiter plate reader and is proportional to the Pichia pastoris HCPs protein concentration. A standard curve is drawn using the standard solution provided, and the Pichia pastoris HCPs protein content can be calculated based on the readings.
[0038] 5. Detection of host DNA residues The Pichia pastoris residual DNA detection kit (PCR-fluorescent probe method) is used for detection. The kit contains reagents for magnetic bead purification and qPCR (fluorescent probe) detection of biological product samples. The qPCR method uses host cell-specific primers and probes to amplify specific DNA fragments in vitro. During the PCR amplification process, the specific probe will be released from the template DNA, and then the fluorescent signal can be detected using a fluorescent quantitative PCR instrument. The fluorescent signal data is analyzed by the detection software of the PCR instrument.
[0039] 6. SEC-HPLC Purity Test Size exclusion chromatography (SEC) separates proteins based on their hydrodynamic radius, which is directly proportional to their molecular weight for most globular proteins. TSKgel UP-SW2000 chromatographic analysis column was used, and a suitable mobile phase was selected. Purity analysis was performed using a Waters high performance liquid chromatography system. The test results are shown in Figure 5 , Figure 5 The SEC-HPLC spectrum is a UV280 absorption curve, and the purity of the main peak can reach 99%.
[0040] 7. Capillary isoelectric focusing (iCIEF) detection Maurice C full-column imaging capillary isoelectric focusing electrophoresis detection technology is used. The protein sample pre-mixed with amphoteric electrolytes is sucked into the capillary cartridge through vacuum. After 10-15 minutes of flushing, injection, separation, and quantification procedures, the protein approaches and focuses on the pH position of its isoelectric point under positive and negative voltages. Every 10 seconds, the CCD camera of the detector records the ultraviolet absorption image of the entire capillary column. This image is the shape of protein separation. The Compass for iCE software will calculate the isoelectric point of the protein sample through the pI Markers on both sides and integrate the sample peaks. The test results are shown in Figure 6 . Figure 6 In the figure, the vertical axis is the UV280 absorption value, the horizontal axis is the isoelectric point pI, and two markers pI7.05 and pI9.99 are used as controls. It can be seen that the isoelectric point pI of the rhPDGF-BB stock solution is 10~11.
[0041] 8. PDGF-BB biological activity detection The PDGF-BB biological activity assay based on reporter gene was used. BALB / C3T3 cells were cultured in DMEM complete medium containing 10% FBS at 37°C and 5% carbon dioxide. After digestion and collection of cells, the complete medium was prepared to contain 5.0×10 4 The cell suspension of 10 cells was inoculated in a 96-well cell culture plate, 100 μl per well, and continued to be cultured at 37°C and 5% carbon dioxide; after 24 hours, the maintenance medium (DMEM containing 0.4% FBS) was replaced and continued to be cultured at 37°C and 5% carbon dioxide; after 24 hours of culture, the maintenance medium was discarded and the recombinant PDGF-BB solution diluted in advance was added, 100 μl per well; after the cells were cultured for 64-72 hours under the action of protein, the cell proliferation activity was detected by the WST-1 method: 10 μl of WST-1 solution was added to each well, and the absorbance value was measured at a wavelength of 450nm (reference wavelength: 630nm) using an enzyme marker after continuing to culture for 3 hours at 37°C and 5% carbon dioxide. The experimental data were processed by the four-parameter regression calculation method to calculate the EC50 value.
[0042] 9. The test result data is summarized in Table 1.
[0043] Table 1. Summary of various test results of the stock solution of Example 1
[0044] Example 3. Optimization of the cation exchange chromatography step of the rh PDGF-BB expression product purification scheme and comparison of the results 1. Filling The preferred cation exchange filler POROS XS of the present invention has a stronger binding force to PDGF-BB, can tolerate the interference of salt concentration in the fermentation broth, has a higher salt concentration for elution of the target peak, can effectively avoid the elution range of most host proteins, can achieve a high degree of separation of PDGF-BB and host proteins, and can achieve high-purity target protein through only one-step capture chromatography, thereby significantly improving the purification efficiency.
[0045] These characteristics are due to the properties of the filler. POROS XS resin is functionalized with a high density of sulfopropyl groups, which are ionized over a wide pH range of 1-14. This gives the resin a high binding capacity over a range of pH and conductivity conditions, increasing the flexibility of method development. The resin backbone of POROS XS consists of a rigid, highly porous, cross-linked poly(styrene-divinylbenzene) with an additional polyhydroxy surface coating to ensure low nonspecific binding. The intrinsic stability and open pore structure of POROS beads allow for rapid binding of macromolecules, consistently producing high dynamic binding capacity under a wide range of flow conditions. Among them, the high density of ligands and the slightly hydrophobic polymer backbone - cross-linked poly(styrene-divinylbenzene) may be the key to the specific adsorption of POROS filler to PDGF-BB (strong hydrophobic protein), which is also the strategy for selecting cation exchange fillers in the present invention.
[0046] In order to reflect that the cation exchange filler selected by the present invention has more advantages in binding to PDGF-BB, a filler comparison experiment was conducted: Capto SP ImpRes, a strong cation filler with an agarose matrix, was selected as a control filler and compared with POROS XS. Capto SP ImpRes is produced by Cytiva and is a strong cation exchange filler. It is composed of a rigid high-flow agarose base frame and a sulfopropyl functional group SP ligand. Its particle size is smaller and has high resolution. The base frame of Capto SP ImpRes filler is hydrophilic agarose, and the specific binding to the strong hydrophobic protein of PDGF-BB is relatively weak. The experiment uses the same batch of rhPDGF-BB stock solution, which is diluted 1 times with purified water as a sample. Both fillers are used for experiments with 1ml pre-packed columns. The two chromatography columns are pre-balanced with 20mM PB, pH7.2, and then loaded with 2mg / ml filler loading. After loading, it is re-balanced with the balance solution, and eluted with 20mM PB, 1M NaCl, pH7.2 according to 0~1M NaCl linear gradient elution 15CV. Chromatographic diagram Figure 7 As shown, from Figure 7 It can be clearly seen that the elution peak of POROS XS is obviously later, and it is eluted only when the conductivity curve Cond is close to 1M NaCl. This shows that POROS XS has a stronger PDGF-BB binding ability than Capto SP ImpRes, and is more conducive to separation from host impurities.
[0047] 2. Elution solvent The cation exchange chromatography elution solvent is preferably arginine, which belongs to basic amino acids. It is positively charged in neutral buffer and can compete with basic proteins such as PDGF-BB, which is conducive to elution. The elution solvent is more powerful than sodium chloride elution ability and is more suitable for eluting PDGF-BB protein. And arginine has the effect of protein protectant, which can prevent the PDGF-BB aggregation precipitation phenomenon caused by high salt elution.
[0048] In order to show that the cation exchange elution solvent selected by the present invention is more advantageous, an elution solvent comparison experiment was carried out: NaCl was selected as the control elution solvent and compared with arginine. The experiment used the same batch of rh PDGF-BB stock solution as the sample, and loaded it on the POROSXS chromatography column (1ml pre-loaded column) twice for the experiment. The balancing liquid 20mM PB, pH7.2 was used to balance the chromatography column. Both times, the sample was loaded at a filler loading of 2mg / ml, and the balancing liquid was used for re-balancing after loading. The first time, 20mM PB, 1M NaCl, pH7.2 was used for linear elution, and the second time, 20mM PB, 1M arginine, pH7.2 was used for linear elution. The main elution peak was collected for SDS-PAGE electrophoresis detection. The SDS-PAGE electrophoresis diagram is shown as follows Figure 8 shown. Figure 8 In the figure, lane 1: molecular weight marker, lane 2: empty lane, lane 3: NaCl eluted sample, lane 4: empty lane, lane 5: arginine eluted sample. It can be clearly seen from the SDS-PAGE electrophoresis that in the POROSXS chromatography process, using arginine as the elution solvent, there are fewer aggregates above the target band in the eluted sample, and the eluted PDGF-BB protein has a higher purity. After electrophoresis purity analysis by gel imaging, the purity of the arginine eluted sample is 99%, and the purity of the NaCl eluted sample is 95%.
[0049] 3. Cation exchange elution flow rate For cation exchange chromatography of PDGF-BB, the method of reducing the elution flow rate to reduce the elution volume is used to further concentrate the eluted sample, which is beneficial to the enrichment and concentration of the eluted sample and realizes direct loading on gel chromatography without the need for additional concentration steps.
[0050] In order to reflect the advantages of reducing the cation exchange elution flow rate selected by the present invention, an elution flow rate comparison experiment was conducted. About 3L of rhPDGF-BB fermentation clarified liquid was loaded on a POROSXS 26ml chromatography column twice. Both times, the impurities were first washed with 20mM PB, 0.35M arginine, pH7.2, and then the target protein was eluted with 20mM PB, 0.8M arginine, pH7.2. When eluting the target protein, a high elution flow rate of 300cm / h was used for the first time, and a low elution flow rate of 100cm / h was used for the second time. The elution volume was examined by the chromatogram. The chromatographic elution spectrum is shown in FIG. Fig. 9 Shown: From Fig. 9 It can be clearly seen that in the POROSXS chromatography process, a low elution flow rate of 100 cm / h is used for elution, and the volume of the elution peak is significantly smaller and the elution peak is higher, indicating that the enrichment and concentration effect is better.
[0051] Example 4. Anionic hydrophobic composite mode chromatography flow-through step The rhPDGF-BB purification process can be expanded to add an anion hydrophobic composite mode chromatography flow-through step after gel chromatography to further remove endotoxins and host impurities. Fermentation broth pretreatment (centrifugation + filtration) → cation exchange chromatography → gel chromatography → anion composite mode chromatography (flow-through mode). Anion composite mode chromatography can choose Captoadhere, Capto adhere ImpRes (Capto adhere ImpRes is produced by Cytiva, it is a strong anion composite mode filler, composed of a rigid high-flow agarose frame and a new multi-mode ligand, its ligand component is N-Benzyl-N-methylethanolamine, which combines multiple complex modes of action such as anion exchange, hydrogen bonding and hydrophobicity. Compared with Capto adhere, it has a smaller particle size and higher resolution), Capto adhere is preferred. The specific process steps are as follows: 1. Preparation of SEC eluent The fermentation broth pretreatment, cation exchange chromatography, and gel chromatography steps were the same as in Example 1 to obtain a SEC eluate.
[0052] 2. Anion complex mode chromatography The Capto adhere chromatography column uses a HiScreen prepacked column with a column height of 10 cm and a CV of 4.7 ml. The chromatography column was connected to the chromatography system and the flow rate was set to 2.35 ml / min (linear flow rate 300 cm / h). The chromatography column was first cleaned with 0.5 M NaOH for 5 CV and then soaked for at least 30 min. The chromatography column was then regenerated with 1 M NaCl for 5 CV. Finally, the chromatography column was equilibrated with an equilibrium buffer (20 mmol / L PB + 0.15 mol / L NaCl, pH 7.2) for 10 CV until the UV280 and the conductivity baseline were stable, and the UV baseline was zeroed. The SEC eluate was loaded onto the chromatography column. After the loading began, the flow-through was collected. When the flow-through UV280 began to rise, the target protein was collected in the 50-50 mAU section. The collected sample was named "ADH flow-through". Finally, the ADH flow-through was sterilized and filtered at 0.22 μm to obtain the rhPDGF-BB stock solution. Capto Adhere is a strongly anionic composite filler. The ligand binds to the target molecule through multiple interactions, such as ionic, hydrophobic and hydrogen bonding. Adhere is often used in the purification stage to remove negatively charged or strongly hydrophobic impurities such as aggregates, host protein HCP, host DNA and endotoxins in the rhPDGF-BB stock solution.
[0053] The HCP and HCD residual results of the stock solution added with Capto adhere chromatography step after gel chromatography were significantly reduced. The stock solution without this step was used as a control. The data are as follows: Table 2. Comparison of technical effects after adding Capto adhere chromatography
[0054] Example 4. The rhPDGF-BB purification process can be expanded to add a membrane chromatography flow-through step after gel chromatography to further remove endotoxins and host impurities. Fermentation broth pretreatment (centrifugation + filtration) → cation exchange chromatography → gel chromatography → anion exchange membrane chromatography (flow-through mode). Membrane chromatography can include Mustang Q, Sartobind Q, Natrix Q, preferably Mustang Q. The specific process steps are as follows: 1. Preparation of SEC eluent The fermentation broth pretreatment, cation exchange chromatography, and gel chromatography steps were the same as in Example 1 to obtain a SEC eluate.
[0055] 2. Anion Exchange Membrane Chromatography Mustang Q membrane chromatography uses Q XT5 membrane with a membrane bed volume (MV) of 5 ml. Connect the membrane chromatography to the chromatography system and set the flow rate to 10 ml / min (2 MV / min). First, wash the chromatography column 5 MV with 0.5 M NaOH and then soak it for at least 30 min. Then regenerate the chromatography column 5 MV with 1 M NaCl. Finally, equilibrate the chromatography column 10 MV with equilibrium buffer (20 mmol / L PB + 0.15 mol / L NaCl, pH 7.2) until the UV280 and conductivity baseline are stable, and perform UV baseline zeroing. Load the SEC eluate on the membrane chromatography. After the loading starts, collect the flow-through. When the flow-through UV280 starts to rise, collect the target protein in the 50-50 mAU section. The collected sample is named "MQ flow-through". Finally, the MQ flow-through is sterilized and filtered at 0.22 μm to obtain the rh PDGF-BB stock solution. Mustang Q is a strong anionic membrane chromatographic filter. The ligands on the membrane surface bind to the target molecule through anion exchange. Mustang Q is often used in the purification stage to remove negatively charged impurities such as host protein HCP, host DNA and endotoxin in the rhPDGF-BB stock solution. Since the principle of Mustang Q is similar to that of Capto adhere, both are based on anion exchange, and its purification effect is similar to that of Capto adhere described in Table 2 of Example 3.
[0056] Example 5. Comparative Example of Two Purification Technology Schemes CN201410206900.1 discloses a platelet-derived growth factor B mutant, its preparation method and use, and its purification process is fermentation broth pretreatment (centrifugal supernatant → filtration → salt supplementation and conductivity adjustment) → hydrophobic chromatography (PhenylSepharose 6 Fast Flow filler, adsorption capture mode, dilution and conductivity adjustment) → cation exchange chromatography (Source 30S filler, intermediate purification, ultrafiltration concentration) → gel chromatography (Superdex 75 prep grad filler, fine purification).
[0057] The present invention compares the technical solution of Example 1 with the purification process in the above-mentioned CN201410206900.1 by conducting three batches of parallel experiments under the same scale conditions to fully compare the advantages and disadvantages of the two purification processes.
[0058] From a process perspective, the technical solution of the present invention has the following advantages: 1. Smooth connection of process steps: POROS XS cation exchange filler has strong binding affinity with PDGF-BB, and the salt concentration in the fermentation broth will not affect the binding of PDGF-BB with the filler, so the fermentation supernatant can be directly loaded onto the POROS XS chromatography column after clarification. In addition, POROS XS has a high binding capacity and can highly enrich PDGF-BB, and the elution volume is small, so it can be directly loaded onto the gel chromatography without additional concentration steps. The samples collected by gel chromatography are directly stored as stock solutions.
[0059] 2. Simple process: The main process steps are only one step of clarification and two steps of chromatography, and there are no additional connecting steps between the steps. There are few key process parameters in the process, which is easy to control the process, with low process risk and high stability. The production efficiency is high, the cost is low, and it is easy to linearly scale up between different scales.
[0060] 3. No hydrophobic chromatography step: The process does not contain a hydrophobic step, which effectively avoids the problems of low dynamic binding capacity of hydrophobic chromatography, low resolution, strong adsorption of the strong hydrophobic protein PDGF-BB and difficulty in elution, and the use of organic elution solvents such as ethylene glycol (which reduces the life of the filler, and ethylene glycol is a flammable and explosive reagent, and the production workshop must meet explosion-proof requirements).
[0061] 4. Comparing the process time and capital cost, this preferred purification process has the following advantages: Based on the simulation of 3 batches of continuous production of 250L fermentation supernatant, compared with Patent 3, the preferred purification process can shorten the production time of stock solution purification from 4 days to 2 days, and the production time can be reduced by 1 time. The main cost savings are shown in Table 3: Table 3. Process cost comparison table
[0062] Through cost comparison, it can be seen that this preferred purification process is easier to achieve cost control for large-scale commercial production.
[0063] 5. Comparing the quality test results of the stock solution, the optimal purification process has the following advantages: (1) Comparison of purity by SDS-PAGE electrophoresis SDS-PAGE electrophoresis pattern Fig.10 As shown, Fig.10 In the figure, lane 1: molecular weight marker, lane 2: CN201410206900.1 hydrophobic chromatography eluate, lane 3: empty lane, lane 4: CN201410206900.1 cation exchange eluate, lane 5: empty lane, lane 6: CN201410206900.1 stock solution, lane 7: empty lane, lane 8: IEC eluate of Example 1, lane 9: empty lane, lane 10: stock solution of Example 1.
[0064] Table 4. Comparison of SDS-PAGE electrophoresis purity analysis (evaluation of electrophoretic purity by gel imaging instrument)
[0065] (2) SEC-HPLC purity comparison SEC-HPLC purity comparison chart Fig.11 As shown, Fig.11 Where A is the stock solution of CN201410206900.1, B is the stock solution of Example 1, and the SEC-HPLC spectrum is the UV280 absorption curve. Fig.11 It can be seen from Table 5 that the main peak purity of the original solution of Example 1 is better.
[0066] Table 5. Comparison of SEC-HPLC purity analysis
[0067] (3) Comparison of capillary isotropic focusing purity Capillary isotropic focusing purity comparison chart Fig.12 As shown, Fig.12 The vertical axis is the UV280 absorption value, and the horizontal axis is the isoelectric point pI. Two markers pI7.05 and pI9.99 are used as controls. A is the stock solution of CN201410206900.1, and B is the stock solution of Example 1. Fig.12 It can be clearly seen that the isoelectric point ranges from pI10 to 11, but the acidic peaks with low pI in the CN201410206900.1 stock solution are significantly more than those in Example 1. This indicates that the charge homogeneity of the Example 1 stock solution is higher.
[0068] (4) Comparison of biological activity purity analysis is shown in Table 6.
[0069] Table 6. Comparison of biological activity purity analysis
[0070] It can be seen from Table 6 that the biological activity of the original solution of Example 1 is higher.
[0071] (5) Protein yield analysis and comparison are shown in Table 7.
[0072] Table 7. Protein yield analysis comparison table
[0073] It can be seen from Table 7 that the yield of target protein in the stock solution of Example 1 is higher.
[0074] (6) Comparison of residual HCPs in host proteins is shown in Table 8.
[0075] Table 8. Comparison of HCP residues in host proteins
[0076] It can be seen from Table 8 that the host protein HCP residue in the original solution of Example 1 is lower.
Claims
1. A method for purifying platelet-derived growth factor-BB, characterized in that: The method comprises the following steps: (1) Pretreatment of the fermentation broth, including centrifugation and filtration to obtain the clarified broth; (2) subjecting the clarified liquid obtained in step (1) to cation exchange chromatography, wherein the filler of the cation exchange chromatography is a strong cation exchange filler with a highly porous rigid resin as a matrix, the filler has an additional polyhydroxy surface coating, a high density of sulfonic acid functional groups are connected to the filler skeleton, and the clear liquid obtained in step (1) is washed with a washing buffer containing arginine and eluted with an elution buffer containing arginine; (3) The eluate obtained in step (2) is subjected to gel chromatography to obtain a platelet-derived growth factor-BB stock solution, wherein the gel chromatography filler is a high-resolution gel filtration filler.
2. The method according to claim 1, characterized in that The concentration of arginine in the washing buffer in step (2) is 0.2-0.5 mol / L, and the concentration of arginine in the elution buffer is 0.6-1 mol / L.
3. The method according to claim 2, characterized in that The elution flow rate of the cation exchange chromatography in step (2) is set to a linear flow rate of 100 cm / h.
4. The method according to claim 3, characterized in that In step (2), the chromatography column is first connected to the chromatography system, and the linear flow rate is set to 300 cm / h; the chromatography column is equilibrated with an equilibrium buffer (20 mmol / L PB + 50 mmol / L arginine, pH 7.2) for 3 to 10 CV until the UV280 and the conductivity baseline are stable, and the UV baseline is reset to zero; the clarified liquid is loaded onto the chromatography column; After loading, use equilibration buffer (20mmol / L PB + 50mmol / L arginine, pH7.2) for equilibration for 10~15CV; use washing buffer (20mmol / L PB + 0.35mol / L arginine, pH7.2) for washing for 15CV; finally, use the elution buffer (20mmol / L PB + 0.8mol / L arginine, pH7.2) for elution for 2~3CV. Collect the target peak, with the collection start and end UV280 ranging from 70 to 50 mAU.
5. The method according to claim 1, characterized in that In step (3), the linear flow rate of gel chromatography was set to 30 cm / h; during chromatography, the chromatography column was first cleaned with 0.5 M NaOH for 1 to 2 CV, and then soaked for at least 30 min. Then, the chromatography column was equilibrated with equilibrium buffer (20 mmol / L PB + 0.15 mol / L NaCl, pH 7.2) for 2 to 3 CV until the UV280 and conductivity baselines were stable, and UV baseline was reset to zero. The IEC eluate was divided into 2 equal parts and loaded onto the gel chromatography column twice, with the loading volume not exceeding 7% CV each time. After loading, the column was eluted with equilibrium buffer (20 mmol / L PB + 0.15 mol / L NaCl, pH 7.2). The interval between two loadings was at least 1CV; when UV280 began to rise slowly, the rising section of about 20~180mAU was the front impurity peak and was not collected; when UV280 continued to rise, the main elution peak began to be collected, and the section from the peak tip to the descending section, that is, the section of about 180~30mAU, was the elution peak of the target protein. The eluate was collected and sterilized and filtered at 0.22μm to obtain the platelet-derived growth factor-BB stock solution.
6. The method according to claim 1, characterized in that After step (3), the method further includes a step of anion composite mode chromatography or anion exchange membrane chromatography in flow-through mode.
7. The method according to claim 6, characterized in that The anion composite mode chromatography in the flow-through mode adopts a composite mode filler composed of a rigid high-flow rate agarose frame and a novel multi-mode ligand N-Benzyl-N-methylethanolamine.
8. The method according to claim 7, characterized in that The flow rate of the anion composite mode chromatography in the flow-through mode is set to a linear flow rate of 300 cm / h. During the chromatography, the chromatography column is first cleaned with 0.5 M NaOH for 5 CV and then soaked for at least 30 min; the chromatography column is then regenerated with 1 M NaCl for 5 CV; finally, the chromatography column is equilibrated with an equilibrium buffer (20 mmol / L PB + 0.15 mol / L NaCl, pH 7.2) for 10 CV until the UV280 and the conductivity baseline are stable, and the UV baseline is reset to zero; the eluate collected in step (3) is loaded onto the chromatography column, and after loading begins, the flow-through is collected, and when the flow-through UV280 starts to rise, the flow-through liquid is collected in the 50-50 mAU segment; finally, the flow-through liquid is subjected to 0.22 μm sterilization filtration to obtain a platelet-derived growth factor-BB stock solution.
9. The method according to claim 6, characterized in that The anion exchange membrane chromatography in the flow-through mode uses a membrane chromatography filter whose surface is covered with a layer of irreversibly cross-linked strong anion exchanger quaternary ammonium group Q.
10. The method according to claim 9, characterized in that The membrane volume of the membrane chromatography filter is 5 ml; the membrane chromatography is connected to the chromatography system, and the membrane volume flow rate is set to 2 MV / min; the chromatography column is first cleaned with 0.5 M NaOH for 5 MV, and then soaked for at least 30 minutes; the chromatography column is then regenerated with 1 M NaCl for 5 MV; finally, the chromatography column is equilibrated with an equilibrium buffer (20 mmol / L PB + 0.15 mol / L NaCl, pH 7.2) for 10 MV until the UV280 and the conductivity baseline are stable, and the UV baseline is reset to zero; the eluate collected in step (3) is loaded onto the membrane chromatography; after loading begins, the flow-through is collected, and when the flow-through UV280 starts to rise, the flow-through liquid is collected in the 50-50 mAU section; finally, the flow-through liquid is subjected to 0.22 μm sterilization filtration to obtain a platelet-derived growth factor-BB stock solution.
